Kadcyla or T-DM1 (ado-trastuzumab emtansine) was first-in-class ADC approved as monotherapy [58] to treat HER2-positive breast cancer patients with progressed disease despite prior trastuzumab and taxane therapy. This evidence concerns the gene ERBB2 and breast carcinoma.